サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1433529

先進治療薬CDMO市場規模、シェア、動向分析レポート：製品別、フェーズ別、適応症別、地域別、セグメント予測、2024年～2030年

Advanced Therapy Medicinal Products CDMO Market Size, Share & Trends Analysis Report By Product (Gene Therapy, Cell Therapy), By Phase, By Indication, By Region, And Segment Forecasts, 2024 - 2030
出版日: | 発行: Grand View Research | ページ情報: 英文 120 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.90円
先進治療薬CDMO市場規模、シェア、動向分析レポート：製品別、フェーズ別、適応症別、地域別、セグメント予測、2024年～2030年
出版日: 2024年01月02日
発行: Grand View Research
ページ情報: 英文 120 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

先進治療薬CDMO市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界の先進治療医薬品CDMO市場規模は2030年までに188億米ドルに達する見込みです。

同市場は、2024年から2030年にかけて18.92%のCAGRを記録すると予測されています。これは、先進治療医薬品の臨床試験の増加と、先進治療の利点に関する研究者の意識の高まりが、先進治療医薬品（ATMP）CDMO市場の成長を牽引しているためです。組織工学は近年、技術開発の恩恵を受けています。損傷した組織や臓器の機能は、この技術を用いて置換されたり回復されたりします。同様に、遺伝子治療や細胞治療も、世界的に罹患率が上昇している希少疾患の治療のために多くの患者を引き付けています。

強力な疾患治療療法への需要が高まる中、主な企業はゲノムレベルで疾患の原因をターゲットとする効果的な遺伝子治療の研究開発に力を注いでいます。ASGCTによると、米国のパイプラインプログラム（第I-III相試験）における細胞・遺伝子治療薬の数は、2021年の483から2022年には529に増加しました。さらにFDAは、製品製造に関する多くの政策を通じ、遺伝子治療分野のイノベーションを常に支援しています。2020年1月、FDAは安全で効率的な遺伝子治療製品の製造と臨床開発に関する6つの最終ガイドラインを発表しました。

さらに、ATMP治療の選択肢に関する意識は、これらの製品の利点を一般に知らせることを目的としたイニシアチブによって推進されており、その結果、先進的な治療法の採用が増加し、CDMOの市場成長に拍車をかけています。例えば、Alliance for Regenerative Medicine Foundation for Cell and Gene Medicineは、再生医療の臨床的・社会的利益を強調し、教育プログラムを通じて一般市民の認識を高める活動を優先しています。

新製品の上市に伴う臨床試験活動の増加は、市場の成長機会を生み出します。2022年現在、前臨床段階にあるATMPは1451品目あり、535品目が第1相から第3相試験で研究されています。2020年8月以降、EMAはこれらのATMPのうち6つを追加承認しており、2023年までにさらに5つが承認される予定です。英国では、2021年には約168件の先進治療医薬品の臨床試験が進行中で、前年の154件から9％増加しました。2021年には第1相臨床試験が32％増加しており、実験的医薬品からヒト初臨床試験へと大きくシフトしていることを示しています。

一方、主要企業は新製品を導入するために様々な戦略的取り組みを行っており、これが市場成長を促進すると予想されます。例えば、2021年3月、CureVac N.V.は、CureVacのmRNAベースのCOVID-19ワクチン候補であるCVnCoVの製造に従事するCelonic Groupとパートナーシップ契約を締結しました。CureVac社のCOVID-19ワクチン候補は、ドイツのハイデルベルクにあるCelonic社のATMPおよび生物製剤の商業製造装置で製造されます。商業供給契約の条件では、セロニック社の施設は1億回分以上のCVnCoVを製造することができます。

先進治療薬CDMO市場レポートハイライト：

  • 遺伝子治療分野が2023年に49.2%以上の最大シェアを占める。資金援助の増加と遺伝子治療の臨床試験数の増加が遺伝子治療分野の需要を牽引しています。
  • 細胞治療分野は、予測期間中に有利な成長を示すと予想されます。細胞治療分野は、新しいタイプの細胞を取り込むことで常に進歩しており、企業にとって市場での地位を高める十分な機会となっています。
  • 2023年に最も大きな売上シェアを占めたのは腫瘍セグメントでした。同分野の優位性は、疾病負担、主要企業による戦略的イニシアティブ、さまざまながんの適応症の治療に使用される先進的な治療法の利用可能性に起因しています。
  • フェーズIセグメントは、研究開発活動の活発化と先進治療薬のヒト試験数の増加により、2023年の市場を独占しました。
  • 2023年の市場シェアは、北米が49.0%で全体を支配しました。これは、アウトソーシング活動の増加や先進治療に対する意識の高まりによるものと考えられます。
  • アジア太平洋地域は、新規ATMPに対する需要の増加と新規治療法開発のための研究開発活動の活発化により、予測期間中に最も速いCAGRで成長すると予想されます。

目次

第1章 調査手法と範囲

第2章 先進治療薬CDMO市場：エグゼクティブサマリー

  • 市場スナップショット
  • 製品のスナップショット
  • フェーズのスナップショット
  • 表示のスナップショット
  • 競合情勢のスナップショット

第3章 先進治療薬CDMO市場変数、動向、および範囲

  • 市場セグメンテーションと範囲
  • 市場系統の見通し
    • 親市場の見通し
    • 関連/付随市場の見通し
  • 市場力学
  • 市場促進要因分析
    • ATMPの臨床試験数の増加
    • アウトソーシング活動の増加
    • 治療に対する意識の高まり
  • 市場抑制要因分析
    • 厳格な規制当局の承認
    • アウトソーシングのコストが高い
  • 先進治療薬CDMO市場分析ツール
    • 業界分析- ポーターのファイブフォース分析
    • PESTLE分析

第4章 先進治療薬CDMO市場：製品の推定・動向分析

  • 製品市場シェア、2023年と2030年
  • セグメントダッシュボード
  • 世界の先進治療薬CDMO市場、製品展望別
  • 以下の市場規模、予測、動向分析、2018年から2030年まで
    • 遺伝子治療
    • 細胞治療
    • 組織工学別
    • その他

第5章 先進治療薬CDMO市場：段階推定・動向分析

  • フェーズ市場シェア、2023年および2030年
  • セグメントダッシュボード
  • 世界の先進治療薬CDMO市場、段階別の見通し
  • 以下の市場規模、予測、動向分析、2018年から2030年まで
    • フェーズI
    • フェーズII
    • フェーズⅢ
    • フェーズIV

第6章 先進治療薬CDMO市場：適応症の推定・動向分析

  • 適応症の市場シェア、2023年および2030年
  • セグメントダッシュボード
  • 世界の先進治療薬CDMO市場、適応症別の見通し
  • 以下の市場規模、予測、動向分析、2018年から2030年まで
    • 腫瘍学
    • 心臓病学
    • 中枢神経系
    • 筋骨格系
    • 感染症
    • 皮膚科
    • 内分泌、代謝、遺伝
    • 免疫学と炎症
    • 眼科
    • 血液学
    • 消化器科
    • その他

第7章 地域ビジネス分析

  • 地域市場シェア分析、2023年および2030年
  • 地域市場ダッシュボード
  • 世界の地域市場のスナップショット
  • 北米
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • スペイン
    • フランス
    • イタリア
    • デンマーク
    • スウェーデン
    • ノルウェー
  • アジア太平洋地域
    • 日本
    • 中国
    • インド
    • 韓国
    • タイ
    • オーストラリア
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • アルゼンチン
  • 中東・アフリカ
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第8章 競合情勢

  • 主要市場参入企業による最近の動向と影響分析
  • 会社/競合の分類
  • ベンダー情勢
    • List Of Key Distributors And Channel Partners
    • Key Customers
    • Key Company Market Share Analysis, 2023
    • CELONIC Group
    • Bio Elpida
    • Rentschler Biopharma SE
    • AGC Biologics
    • Catalent, Inc.
    • Lonza
    • Wuxi Advanced Therapies
    • Minaris Regenerative Medicine
    • Patheon, Inc.
    • CGT Catapult
図表

List of Tables

  • Table 1 List of Abbreviation
  • Table 2 North America Advanced Therapy Medicinal Products CDMO Market, by Region, 2018 - 2030 (USD Million)
  • Table 3 North America Advanced Therapy Medicinal Products CDMO Market, by Product, 2018 - 2030 (USD Million)
  • Table 4 North America Advanced Therapy Medicinal Products CDMO Market, by Phase, 2018 - 2030 (USD Million)
  • Table 5 North America Advanced Therapy Medicinal Products CDMO Market, Indication, 2018 - 2030 (USD Million)
  • Table 6 U.S. Advanced Therapy Medicinal Products CDMO Market, by Product, 2018 - 2030 (USD Million)
  • Table 7 U.S. Advanced Therapy Medicinal Products CDMO Market, by Phase, 2018 - 2030 (USD Million)
  • Table 8 U.S. Advanced Therapy Medicinal Products CDMO Market, Indication, 2018 - 2030 (USD Million)
  • Table 9 Canada Advanced Therapy Medicinal Products CDMO Market, by Product, 2018 - 2030 (USD Million)
  • Table 10 Canada Advanced Therapy Medicinal Products CDMO Market, by Phase, 2018 - 2030 (USD Million)
  • Table 11 Canada Advanced Therapy Medicinal Products CDMO Market, Indication, 2018 - 2030 (USD Million)
  • Table 12 Europe Advanced Therapy Medicinal Products CDMO Market, by Region, 2018 - 2030 (USD Million)
  • Table 13 Europe Advanced Therapy Medicinal Products CDMO Market, by Product, 2018 - 2030 (USD Million)
  • Table 14 Europe Advanced Therapy Medicinal Products CDMO Market, by Phase, 2018 - 2030 (USD Million)
  • Table 15 Europe Advanced Therapy Medicinal Products CDMO Market, Indication, 2018 - 2030 (USD Million)
  • Table 16 UK Advanced Therapy Medicinal Products CDMO Market, by Product, 2018 - 2030 (USD Million)
  • Table 17 UK Advanced Therapy Medicinal Products CDMO Market, by Phase, 2018 - 2030 (USD Million)
  • Table 18 UK Advanced Therapy Medicinal Products CDMO Market, Indication, 2018 - 2030 (USD Million)
  • Table 19 Germany Advanced Therapy Medicinal Products CDMO Market, by Product, 2018 - 2030 (USD Million)
  • Table 20 Germany Advanced Therapy Medicinal Products CDMO Market, by Phase, 2018 - 2030 (USD Million)
  • Table 21 Germany Advanced Therapy Medicinal Products CDMO Market, Indication, 2018 - 2030 (USD Million)
  • Table 22 France Advanced Therapy Medicinal Products CDMO Market, by Product, 2018 - 2030 (USD Million)
  • Table 23 France Advanced Therapy Medicinal Products CDMO Market, by Phase, 2018 - 2030 (USD Million)
  • Table 24 France Advanced Therapy Medicinal Products CDMO Market, Indication, 2018 - 2030 (USD Million)
  • Table 25 Italy Advanced Therapy Medicinal Products CDMO Market, by Product, 2018 - 2030 (USD Million)
  • Table 26 Italy Advanced Therapy Medicinal Products CDMO Market, by Phase, 2018 - 2030 (USD Million)
  • Table 27 Italy Advanced Therapy Medicinal Products CDMO Market, Indication, 2018 - 2030 (USD Million)
  • Table 28 Spain Advanced Therapy Medicinal Products CDMO Market, by Product, 2018 - 2030 (USD Million)
  • Table 29 Spain Advanced Therapy Medicinal Products CDMO Market, by Phase, 2018 - 2030 (USD Million)
  • Table 30 Spain Advanced Therapy Medicinal Products CDMO Market, Indication, 2018 - 2030 (USD Million)
  • Table 31 Sweden Advanced Therapy Medicinal Products CDMO Market, by Product, 2018 - 2030 (USD Million)
  • Table 32 Sweden Advanced Therapy Medicinal Products CDMO Market, by Phase, 2018 - 2030 (USD Million)
  • Table 33 Sweden Advanced Therapy Medicinal Products CDMO Market, Indication, 2018 - 2030 (USD Million)
  • Table 34 Norway Advanced Therapy Medicinal Products CDMO Market, by Product, 2018 - 2030 (USD Million)
  • Table 35 Norway Advanced Therapy Medicinal Products CDMO Market, by Phase, 2018 - 2030 (USD Million)
  • Table 36 Norway Advanced Therapy Medicinal Products CDMO Market, Indication, 2018 - 2030 (USD Million)
  • Table 37 Denmark Advanced Therapy Medicinal Products CDMO Market, by Product, 2018 - 2030 (USD Million)
  • Table 38 Denmark Advanced Therapy Medicinal Products CDMO Market, by Phase, 2018 - 2030 (USD Million)
  • Table 39 Denmark Advanced Therapy Medicinal Products CDMO Market, Indication, 2018 - 2030 (USD Million)
  • Table 40 Asia Pacific Advanced Therapy Medicinal Products CDMO Market, by Region, 2018 - 2030 (USD Million)
  • Table 41 Asia Pacific Advanced Therapy Medicinal Products CDMO Market, by Product, 2018 - 2030 (USD Million)
  • Table 42 Asia Pacific Advanced Therapy Medicinal Products CDMO Market, by Phase, 2018 - 2030 (USD Million)
  • Table 43 Asia Pacific Advanced Therapy Medicinal Products CDMO Market, Indication, 2018 - 2030 (USD Million)
  • Table 44 Japan Advanced Therapy Medicinal Products CDMO Market, by Product, 2018 - 2030 (USD Million)
  • Table 45 Japan Advanced Therapy Medicinal Products CDMO Market, by Phase, 2018 - 2030 (USD Million)
  • Table 46 Japan Advanced Therapy Medicinal Products CDMO Market, Indication, 2018 - 2030 (USD Million)
  • Table 47 China Advanced Therapy Medicinal Products CDMO Market, by Product, 2018 - 2030 (USD Million)
  • Table 48 China Advanced Therapy Medicinal Products CDMO Market, by Phase, 2018 - 2030 (USD Million)
  • Table 49 China Advanced Therapy Medicinal Products CDMO Market, Indication, 2018 - 2030 (USD Million)
  • Table 50 India Advanced Therapy Medicinal Products CDMO Market, by Product, 2018 - 2030 (USD Million)
  • Table 51 India Advanced Therapy Medicinal Products CDMO Market, by Phase, 2018 - 2030 (USD Million)
  • Table 52 India Advanced Therapy Medicinal Products CDMO Market, Indication, 2018 - 2030 (USD Million)
  • Table 53 Australia Advanced Therapy Medicinal Products CDMO Market, by Product, 2018 - 2030 (USD Million)
  • Table 54 Australia Advanced Therapy Medicinal Products CDMO Market, by Phase, 2018 - 2030 (USD Million)
  • Table 55 Australia Advanced Therapy Medicinal Products CDMO Market, Indication, 2018 - 2030 (USD Million)
  • Table 56 South Korea Advanced Therapy Medicinal Products CDMO Market, by Product, 2018 - 2030 (USD Million)
  • Table 57 South Korea Advanced Therapy Medicinal Products CDMO Market, by Phase, 2018 - 2030 (USD Million)
  • Table 58 South Korea Advanced Therapy Medicinal Products CDMO Market, Indication, 2018 - 2030 (USD Million)
  • Table 59 Thailand Advanced Therapy Medicinal Products CDMO Market, by Product, 2018 - 2030 (USD Million)
  • Table 60 Thailand Advanced Therapy Medicinal Products CDMO Market, by Phase, 2018 - 2030 (USD Million)
  • Table 61 Thailand Advanced Therapy Medicinal Products CDMO Market, Indication, 2018 - 2030 (USD Million)
  • Table 62 Latin America Advanced Therapy Medicinal Products CDMO Market, by Region, 2018 - 2030 (USD Million)
  • Table 63 Latin America Advanced Therapy Medicinal Products CDMO Market, by Product, 2018 - 2030 (USD Million)
  • Table 64 Latin America Advanced Therapy Medicinal Products CDMO Market, by Phase, 2018 - 2030 (USD Million)
  • Table 65 Latin America Advanced Therapy Medicinal Products CDMO Market, Indication, 2018 - 2030 (USD Million)
  • Table 66 Brazil Advanced Therapy Medicinal Products CDMO Market, by Product, 2018 - 2030 (USD Million)
  • Table 67 Brazil Advanced Therapy Medicinal Products CDMO Market, by Phase, 2018 - 2030 (USD Million)
  • Table 68 Brazil Advanced Therapy Medicinal Products CDMO Market, Indication, 2018 - 2030 (USD Million)
  • Table 69 Argentina Advanced Therapy Medicinal Products CDMO Market, by Product, 2018 - 2030 (USD Million)
  • Table 70 Argentina Advanced Therapy Medicinal Products CDMO Market, by Phase, 2018 - 2030 (USD Million)
  • Table 71 Argentina Advanced Therapy Medicinal Products CDMO Market, Indication, 2018 - 2030 (USD Million)
  • Table 72 Mexico Advanced Therapy Medicinal Products CDMO Market, by Product, 2018 - 2030 (USD Million)
  • Table 73 Mexico Advanced Therapy Medicinal Products CDMO Market, by Phase, 2018 - 2030 (USD Million)
  • Table 74 Mexico Advanced Therapy Medicinal Products CDMO Market, Indication, 2018 - 2030 (USD Million)
  • Table 75 MEA Advanced Therapy Medicinal Products CDMO Market, by Region, 2018 - 2030 (USD Million)
  • Table 76 MEA Advanced Therapy Medicinal Products CDMO Market, by Product, 2018 - 2030 (USD Million)
  • Table 77 MEA Advanced Therapy Medicinal Products CDMO Market, by Phase, 2018 - 2030 (USD Million)
  • Table 78 MEA Advanced Therapy Medicinal Products CDMO Market, Indication, 2018 - 2030 (USD Million)
  • Table 79 South Africa Advanced Therapy Medicinal Products CDMO Market, by Product, 2018 - 2030 (USD Million)
  • Table 80 South Africa Advanced Therapy Medicinal Products CDMO Market, by Phase, 2018 - 2030 (USD Million)
  • Table 81 South Africa Advanced Therapy Medicinal Products CDMO Market, Indication, 2018 - 2030 (USD Million)
  • Table 82 Saudi Arabia Advanced Therapy Medicinal Products CDMO Market, by Product, 2018 - 2030 (USD Million)
  • Table 83 Saudi Arabia Advanced Therapy Medicinal Products CDMO Market, by Phase, 2018 - 2030 (USD Million)
  • Table 84 Saudi Arabia Advanced Therapy Medicinal Products CDMO Market, Indication, 2018 - 2030 (USD Million)
  • Table 85 UAE Advanced Therapy Medicinal Products CDMO Market, by Product, 2018 - 2030 (USD Million)
  • Table 86 UAE Advanced Therapy Medicinal Products CDMO Market, by Phase, 2018 - 2030 (USD Million)
  • Table 87 UAE Advanced Therapy Medicinal Products CDMO Market, Indication, 2018 - 2030 (USD Million)
  • Table 88 Kuwait Advanced Therapy Medicinal Products CDMO Market, by Product, 2018 - 2030 (USD Million)
  • Table 89 Kuwait Advanced Therapy Medicinal Products CDMO Market, by Phase, 2018 - 2030 (USD Million)
  • Table 90 Kuwait Advanced Therapy Medicinal Products CDMO Market, Test type, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market Research Process
  • Fig. 2 Data Triangulation Techniques
  • Fig. 3 Primary Research Pattern
  • Fig. 4 Primary Interviews In North America
  • Fig. 5 Primary Interviews In Europe
  • Fig. 6 Primary Interviews In Asia Pacific
  • Fig. 7 Primary Interviews In Latin America
  • Fig. 8 Primary Interviews In Middle East & Africa
  • Fig. 9 Market Research Approaches
  • Fig. 10 Value-Chain-Based Sizing & Forecasting
  • Fig. 11 QFD Modeling For Market Share Assessment
  • Fig. 12 Market Formulation & Validation
  • Fig. 13 Advanced Therapy Medicinal Products CDMO Market: Market Outlook
  • Fig. 14 Advanced Therapy Medicinal Products CDMO Competitive Insights
  • Fig. 15 Parent Market Outlook
  • Fig. 16 Related/Ancillary Market Outlook
  • Fig. 17 Penetration And Growth Prospect Mapping
  • Fig. 18 Industry Value Chain Analysis
  • Fig. 19 Advanced Therapy Medicinal Products CDMO Market Driver Impact
  • Fig. 20 Advanced Therapy Medicinal Products CDMO Market Restraint Impact
  • Fig. 21 Advanced Therapy Medicinal Products CDMO Market Strategic Initiatives Analysis
  • Fig. 22 Advanced Therapy Medicinal Products CDMO Market: Product Movement Analysis
  • Fig. 23 Advanced Therapy Medicinal Products CDMO Market: Product Outlook And Key Takeaways
  • Fig. 24 Gene Therapy Market Estimates And Forecast, 2018 - 2030
  • Fig. 25 Cell Therapy Estimates And Forecast, 2018 - 2030
  • Fig. 26 Tissue Engineered Estimates And Forecast, 2018 - 2030
  • Fig. 27 Others Estimates And Forecast, 2018 - 2030
  • Fig. 28 Advanced Therapy Medicinal Products CDMO Market: Phase Movement Analysis
  • Fig. 29 Advanced Therapy Medicinal Products CDMO Market: Phase Outlook And Key Takeaways
  • Fig. 30 Phase I Market Estimates And Forecasts, 2018 - 2030
  • Fig. 31 Phase II Market Estimates And Forecasts, 2018 - 2030
  • Fig. 32 Phase III Market Estimates And Forecasts, 2018 - 2030
  • Fig. 33 Phase IV Market Estimates And Forecasts, 2018 - 2030
  • Fig. 34 Advanced Therapy Medicinal Products CDMO Market: Indication Movement Analysis
  • Fig. 35 Advanced Therapy Medicinal Products CDMO Market: Indication Outlook And Key Takeaways
  • Fig. 36 Oncology Market Estimates And Forecasts, 2018 - 2030
  • Fig. 37 Cardiology Market Estimates And Forecasts,2018 - 2030
  • Fig. 38 Central Nervous System Estimates And Forecasts, 2018 - 2030
  • Fig. 39 Musculoskeletal Estimates And Forecasts, 2018 - 2030
  • Fig. 40 Infectious Disease Estimates And Forecasts, 2018 - 2030
  • Fig. 41 Dermatology Estimates And Forecasts, 2018 - 2030
  • Fig. 42 Others Estimates And Forecasts, 2018 - 2030
  • Fig. 43 Global Advanced Therapy Medicinal Products CDMO Market: Regional Movement Analysis
  • Fig. 44 Global Advanced Therapy Medicinal Products CDMO Market: Regional Outlook And Key Takeaways
  • Fig. 45 Global Advanced Therapy Medicinal Products CDMO Market Share And Leading Players
  • Fig. 46 North America Market Share And Leading Players
  • Fig. 47 Europe Market Share And Leading Players
  • Fig. 48 Asia Pacific Market Share And Leading Players
  • Fig. 49 Latin America Market Share And Leading Players
  • Fig. 50 Middle East & Africa Market Share And Leading Players
  • Fig. 51 North America: SWOT
  • Fig. 52 Europe SWOT
  • Fig. 53 Asia Pacific SWOT
  • Fig. 54 Latin America SWOT
  • Fig. 55 MEA SWOT
  • Fig. 56 North America
  • Fig. 57 North America Market Estimates And Forecasts, 2018 - 2030
  • Fig. 58 U.S.
  • Fig. 59 U.S. Market Estimates And Forecasts, 2018 - 2030
  • Fig. 60 Canada
  • Fig. 61 Canada Market Estimates And Forecasts, 2018 - 2030
  • Fig. 62 Europe
  • Fig. 63 Europe Market Estimates And Forecasts, 2018 - 2030
  • Fig. 64 UK
  • Fig. 65 UK Market Estimates And Forecasts, 2018 - 2030
  • Fig. 66 Germany
  • Fig. 67 Germany Market Estimates And Forecasts, 2018 - 2030
  • Fig. 68 France
  • Fig. 69 France Market Estimates And Forecasts, 2018 - 2030
  • Fig. 70 Italy
  • Fig. 71 Italy Market Estimates And Forecasts, 2018 - 2030
  • Fig. 72 Spain
  • Fig. 73 Spain Market Estimates And Forecasts, 2018 - 2030
  • Fig. 74 Denmark
  • Fig. 75 Denmark Market Estimates And Forecasts, 2018 - 2030
  • Fig. 76 Sweden
  • Fig. 77 Sweden Market Estimates And Forecasts, 2018 - 2030
  • Fig. 78 Norway
  • Fig. 79 Norway Market Estimates And Forecasts, 2018 - 2030
  • Fig. 80 Asia Pacific
  • Fig. 81 Asia Pacific Market Estimates And Forecasts, 2018 - 2030
  • Fig. 82 China
  • Fig. 83 China Market Estimates And Forecasts, 2018 - 2030
  • Fig. 84 Japan
  • Fig. 85 Japan Market Estimates And Forecasts, 2018 - 2030
  • Fig. 86 India
  • Fig. 87 India Market Estimates And Forecasts, 2018 - 2030
  • Fig. 88 Thailand
  • Fig. 89 Thailand Market Estimates And Forecasts, 2018 - 2030
  • Fig. 90 South Korea
  • Fig. 91 South Korea Market Estimates And Forecasts, 2018 - 2030
  • Fig. 92 Australia
  • Fig. 93 Australia Market Estimates And Forecasts, 2018 - 2030
  • Fig. 94 Latin America
  • Fig. 95 Latin America Market Estimates And Forecasts, 2018 - 2030
  • Fig. 96 Brazil
  • Fig. 97 Brazil Market Estimates And Forecasts, 2018 - 2030
  • Fig. 98 Mexico
  • Fig. 99 Mexico Market Estimates And Forecasts, 2018 - 2030
  • Fig. 100 Argentina
  • Fig. 101 Argentina Market Estimates And Forecasts, 2018 - 2030
  • Fig. 102 Middle East And Africa
  • Fig. 103 Middle East And Africa Market Estimates And Forecasts, 2018 - 2030
  • Fig. 104 South Africa
  • Fig. 105 South Africa Market Estimates And Forecasts, 2018 - 2030
  • Fig. 106 Saudi Arabia
  • Fig. 107 Saudi Arabia Market Estimates And Forecasts, 2018 - 2030
  • Fig. 108 UAE
  • Fig. 109 UAE Market Estimates And Forecasts, 2018 - 2030
  • Fig. 110 Kuwait
  • Fig. 111 Kuwait Market Estimates And Forecasts, 2018 - 2030
  • Fig. 112 Market Share Of Key Market Players - Advanced Therapy Medicinal Products CDMO Market
目次
Product Code: GVR-4-68039-676-6

Advanced Therapy Medicinal Products CDMO Market Growth & Trends:

The global advanced therapy medicinal products CDMO market size is expected to reach USD 18.8 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to register a CAGR of 18.92% from 2024 to 2030, owing to rising clinical trials for advanced therapy medicinal products and the increasing awareness among researchers about the benefits of advanced therapies, driving the advanced therapy medicinal products (ATMP) CDMO market growth. Tissue engineering has greatly benefited in recent years from technological development. The damaged tissues and organ function are replaced or restored using this technique. Similarly, gene and cell therapy are attracting a lot of patients for the treatment of rare diseases, whose incidence is rising globally.

With rising demand for robust disease treatment therapies, key players have focused their efforts to ramp up research and development for effective gene therapies that target the cause of disorder at a genomic level. According to ASGCT, the number of cell and gene therapies in the U.S. pipeline programs (phase I-III trials) increased from 483 in 2021 to 529 in 2022. Furthermore, the FDA delivers constant support for innovations in the gene therapy field via a number of policies with regard to product manufacturing. In January 2020, the agency released six final guidelines on the manufacturing and clinical development of safe & efficient gene therapy products.

Moreover, awareness about ATMP treatment options is being driven by initiatives aimed at informing the public about the benefits of these products, which, in turn, is leading to increased adoption of advanced therapies and fueling market growth for CDMOs. For instance, Alliance for Regenerative Medicine Foundation for Cell and Gene Medicine prioritizes activities for increasing public awareness through educational programs, underlining the clinical & societal benefits of regenerative medicine.

Increasing clinical trial activity along with new product launches generates growth opportunities for the market. As of 2022, there are 1451 ATMPs in preclinical stages and 535 are being studied in Phase 1 to 3 studies. Since August 2020, EMA has approved six of these additional ATMPs, and five more will be approved by 2023. In the UK, there were approximately 168 advanced therapy medicinal product trials underway in 2021, up from the 154 studies reported the year before, which is a 9% increase. 2021 saw a 32% increase in phase 1 trials, indicating a significant shift from experimental medicines to first-in-human studies.

On the other hand, key players are undertaking various strategic initiatives to introduce novel products, which is expected to propel market growth. For instance, in March 2021, CureVac N.V. signed a partnership agreement with Celonic Group, engaged in the manufacture of CVnCoV, CureVac's mRNA-based COVID-19 vaccine candidate. CureVac's COVID-19 vaccine candidate is manufactured at Celonic's commercial manufacturing unit for ATMPs and biologics in Heidelberg, Germany. Under the terms of the commercial supply agreement, the Celonic facility could produce over 100 million doses of CVnCoV.

Advanced Therapy Medicinal Products CDMO Market Report Highlights:

  • The gene therapy segment held the largest share of over 49.2% in 2023. Increase in financial support and rise in number of clinical trials for gene therapies are driving demand for the gene therapy segment.
  • The cell therapy segment is expected to show lucrative growth over the forecast period. The field of cellular therapeutics is constantly advancing with inclusion of new cell types, which, in turn, provides ample opportunities for companies to enhance their market positions.
  • The oncology segment accounted for the largest revenue share in 2023. The segment's dominance is attributed to disease burden, strategic initiatives undertaken by key players, and availability of advanced therapies used for treating various cancer indications.
  • The phase I segment dominated the market in 2023 due to growing R&D activities and increasing number of human trials for advanced therapies.
  • North America dominated the overall market share of 49.0% in 2023. This can be attributed to increasing outsourcing activities and rising awareness about advanced therapy.
  • The Asia Pacific region is expected to grow at the fastest CAGR over the forecast period due to the increasing demand for novel ATMPs and rising R&D activities to develop novel therapies.

Table of Contents

Chapter 1. Methodology And Scope

  • 1.1. Market Segmentation And Scope
    • 1.1.1. Segment Definitions
      • 1.1.1.1. Product Segment
      • 1.1.1.2. Phase Segment
      • 1.1.1.3. Indication Segment
  • 1.2. Regional Scope
  • 1.3. Estimates And Forecast Timeline
  • 1.4. Objectives
    • 1.4.1. Objective - 1
    • 1.4.2. Objective - 2
  • 1.5. Research Methodology
  • 1.6. Information Procurement
    • 1.6.1. Purchased Database
    • 1.6.2. GVR's Internal Database
    • 1.6.3. Secondary Sources
    • 1.6.4. Primary Research
  • 1.7. Information or Data Analysis
    • 1.7.1. Data Analysis Models
  • 1.8. Market Formulation & Validation
  • 1.9. Model Details
    • 1.9.1. Commodity Flow Analysis
  • 1.10. List Of Primary Sources
  • 1.11. List Of Abbreviations

Chapter 2. Advanced Therapy Medicinal Products CDMO Market: Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Products Snapshots
  • 2.3. Phase Snapshots
  • 2.4. Indication Snapshot
  • 2.5. Competitive Landscape Snapshot

Chapter 3. Advanced Therapy Medicinal Products CDMO Market Variables, Trends, & Scope

  • 3.1. Market Segmentation And Scope
  • 3.2. Market Lineage Outlook
    • 3.2.1. Parent Market Outlook
    • 3.2.2. Related/Ancillary Market Outlook
  • 3.3. Market Dynamics
  • 3.4. Market Drivers Analysis
    • 3.4.1. Rising number of clinical trials for ATMPs
    • 3.4.2. Increasing outsourcing activities
    • 3.4.3. Growing awareness of the treatment
  • 3.5. Market Restraint Analysis
    • 3.5.1. Stringent regulatory approvals
    • 3.5.2. High cost of outsourcing
  • 3.6. Advanced Therapy Medicinal Products CDMO Market Analysis Tools
    • 3.6.1. Industry Analysis - Porter's
      • 3.6.1.1. Supplier Power
      • 3.6.1.2. Buyer Power
      • 3.6.1.3. Substitution Threat
      • 3.6.1.4. Threat Of New Entrant
      • 3.6.1.5. Competitive Rivalry
    • 3.6.2. PESTLE Analysis
      • 3.6.2.1. Political Landscape
      • 3.6.2.2. Technological Landscape
      • 3.6.2.3. Economic Landscape

Chapter 4. Advanced Therapy Medicinal Products CDMO: Products Estimates & Trend Analysis

  • 4.1. Product Market Share, 2023 & 2030
  • 4.2. Segment Dashboard
  • 4.3. Global Advanced Therapy Medicinal Products CDMO Market, By Product Outlook
  • 4.4. Market Size & Forecasts And Trend Analyses, 2018 To 2030 For The Following
    • 4.4.1. Gene Therapy
      • 4.4.1.1. Market Estimates And Forecasts, 2018 To 2030 (USD Million)
    • 4.4.2. Cell Therapy
      • 4.4.2.1. Market Estimates And Forecasts, 2018 To 2030 (USD Million)
    • 4.4.3. Tissue Engineered
      • 4.4.3.1. Market Estimates And Forecasts, 2018 To 2030 (USD Million)
    • 4.4.4. Others
      • 4.4.4.1. Market Estimates And Forecasts, 2018 To 2030 (USD Million)

Chapter 5. Advanced Therapy Medicinal Products CDMO: Phase Estimates & Trend Analysis

  • 5.1. Phase Market Share, 2023 & 2030
  • 5.2. Segment Dashboard
  • 5.3. Global Advanced Therapy Medicinal Products CDMO Market, By Phase Outlook
  • 5.4. Market Size & Forecasts And Trend Analyses, 2018 To 2030 For The Following
    • 5.4.1. Phase I
      • 5.4.1.1. Market Estimates And Forecasts, 2018 To 2030 (USD Million)
    • 5.4.2. Phase II
      • 5.4.2.1. Market Estimates And Forecasts, 2018 To 2030 (USD Million)
    • 5.4.3. Phase III
      • 5.4.3.1. Market Estimates And Forecasts, 2018 To 2030 (USD Million)
    • 5.4.4. Phase IV
      • 5.4.4.1. Market Estimates And Forecasts, 2018 To 2030 (USD Million)

Chapter 6. Advanced Therapy Medicinal Products CDMO: Indication Estimates & Trend Analysis

  • 6.1. Indication Market Share, 2023 & 2030
  • 6.2. Segment Dashboard
  • 6.3. Global Advanced Therapy Medicinal Products CDMO Market, By Indication Outlook
  • 6.4. Market Size & Forecasts And Trend Analyses, 2018 To 2030 For The Following
    • 6.4.1. Oncology
      • 6.4.1.1. Market Estimates And Forecasts, 2018 To 2030 (USD Million)
    • 6.4.2. Cardiology
      • 6.4.2.1. Market Estimates And Forecasts, 2018 To 2030 (USD Million)
    • 6.4.3. Central Nervous System
      • 6.4.3.1. Market Estimates And Forecasts, 2018 To 2030 (USD Million)
    • 6.4.4. Musculoskeletal
      • 6.4.4.1. Market Estimates And Forecasts, 2018 To 2030 (USD Million)
    • 6.4.5. Infectious Disease
      • 6.4.5.1. Market Estimates And Forecasts, 2018 To 2030 (USD Million)
    • 6.4.6. Dermatology
      • 6.4.6.1. Market Estimates And Forecasts, 2018 To 2030 (USD Million)
    • 6.4.7. Endocrine, Metabolic, Genetic
      • 6.4.7.1. Market Estimates And Forecasts, 2018 To 2030 (USD Million)
    • 6.4.8. Immunology & Inflammation
      • 6.4.8.1. Market Estimates And Forecasts, 2018 To 2030 (USD Million)
    • 6.4.9. Ophthalmology
      • 6.4.9.1. Market Estimates And Forecasts, 2018 To 2030 (USD Million)
    • 6.4.10. Hematology
      • 6.4.10.1. Market Estimates And Forecasts, 2018 To 2030 (USD Million)
    • 6.4.11. Gastroenterology
      • 6.4.11.1. Market Estimates And Forecasts, 2018 To 2030 (USD Million)
    • 6.4.12. Others
      • 6.4.12.1. Market Estimates And Forecasts, 2018 To 2030 (USD Million)

Chapter 7. Regional Business Analysis

  • 7.1. Regional Market Share Analysis, 2023 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Global Regional Market Snapshot
  • 7.4. Marker Size, & Forecasts Trend Analysis, 2018 To 2030:
  • 7.5. North America
    • 7.5.1. U.S.
      • 7.5.1.1. Key Country Dynamics
      • 7.5.1.2. Competitive Scenario
      • 7.5.1.3. Regulatory Framework
      • 7.5.1.4. U.S. Market Estimates And Forecasts, 2018 To 2030 (USD Million)
    • 7.5.2. Canada
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Competitive Scenario
      • 7.5.2.3. Regulatory Framework
      • 7.5.2.4. Canada Market Estimates And Forecasts, 2018 To 2030 (USD Million)
  • 7.6. Europe
    • 7.6.1. UK
      • 7.6.1.1. Key Country Dynamics
      • 7.6.1.2. Competitive Scenario
      • 7.6.1.3. Regulatory Framework
      • 7.6.1.4. UK Market Estimates And Forecasts, 2018 To 2030 (USD Million)
    • 7.6.2. Germany
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Competitive Scenario
      • 7.6.2.3. Regulatory Framework
      • 7.6.2.4. Germany Market Estimates And Forecasts, 2018 To 2030 (USD Million)
    • 7.6.3. Spain
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Competitive Scenario
      • 7.6.3.3. Regulatory Framework
      • 7.6.3.4. Spain Market Estimates And Forecasts, 2018 To 2030 (USD Million)
    • 7.6.4. France
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Competitive Scenario
      • 7.6.4.3. Regulatory Framework
      • 7.6.4.4. France Market Estimates And Forecasts, 2018 To 2030 (USD Million)
    • 7.6.5. Italy
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Competitive Scenario
      • 7.6.5.3. Regulatory Framework
      • 7.6.5.4. Italy Market Estimates And Forecasts, 2018 To 2030 (USD Million)
    • 7.6.6. Denmark
      • 7.6.6.1. Key Country Dynamics
      • 7.6.6.2. Competitive Scenario
      • 7.6.6.3. Regulatory Framework
      • 7.6.6.4. Denmark Market Estimates And Forecasts, 2018 To 2030 (USD Million)
    • 7.6.7. Sweden
      • 7.6.7.1. Key Country Dynamics
      • 7.6.7.2. Competitive Scenario
      • 7.6.7.3. Regulatory Framework
      • 7.6.7.4. Sweden Market Estimates And Forecasts, 2018 To 2030 (USD Million)
    • 7.6.8. Norway
      • 7.6.8.1. Key Country Dynamics
      • 7.6.8.2. Competitive Scenario
      • 7.6.8.3. Regulatory Framework
      • 7.6.8.4. Norway Market Estimates And Forecasts, 2018 To 2030 (USD Million)
  • 7.7. Asia Pacific
    • 7.7.1. Japan
      • 7.7.1.1. Key Country Dynamics
      • 7.7.1.2. Competitive Scenario
      • 7.7.1.3. Regulatory Framework
      • 7.7.1.4. Japan Market Estimates And Forecasts, 2018 To 2030 (USD Million)
    • 7.7.2. China
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Competitive Scenario
      • 7.7.2.3. Regulatory Framework
      • 7.7.2.4. China Market Estimates And Forecasts, 2018 To 2030 (USD Million)
    • 7.7.3. India
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Competitive Scenario
      • 7.7.3.3. Regulatory Framework
      • 7.7.3.4. India Market Estimates And Forecasts, 2018 To 2030 (USD Million)
    • 7.7.4. South Korea
      • 7.7.4.1. Key Country Dynamics
      • 7.7.4.2. Competitive Scenario
      • 7.7.4.3. Regulatory Framework
      • 7.7.4.4. South Korea Market Estimates And Forecasts, 2018 To 2030 (USD Million)
    • 7.7.5. Thailand
      • 7.7.5.1. Key Country Dynamics
      • 7.7.5.2. Competitive Scenario
      • 7.7.5.3. Regulatory Framework
      • 7.7.5.4. Thailand Market Estimates And Forecasts, 2018 To 2030 (USD Million)
    • 7.7.6. Australia
      • 7.7.6.1. Key Country Dynamics
      • 7.7.6.2. Competitive Scenario
      • 7.7.6.3. Regulatory Framework
      • 7.7.6.4. Australia Market Estimates And Forecasts, 2018 To 2030 (USD Million)
  • 7.8. Latin America
    • 7.8.1. Brazil
      • 7.8.1.1. Key Country Dynamics
      • 7.8.1.2. Competitive Scenario
      • 7.8.1.3. Regulatory Framework
      • 7.8.1.4. Brazil Market Estimates And Forecasts, 2018 To 2030 (USD Million)
    • 7.8.2. Mexico
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. Competitive Scenario
      • 7.8.2.3. Regulatory Framework
      • 7.8.2.4. Mexico Advanced Therapy Medicinal Products CDMO Market, 2018 - 2030 (USD Million)
    • 7.8.3. Argentina
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. Competitive Scenario
      • 7.8.3.3. Regulatory Framework
      • 7.8.3.4. Argentina Market Estimates And Forecasts, 2018 To 2030 (USD Million)
  • 7.9. MEA
    • 7.9.1. MEA Advanced Therapy Medicinal Products CDMO Market, 2018 - 2030 (USD Million)
    • 7.9.2. South Africa
      • 7.9.2.1. Key Country Dynamics
      • 7.9.2.2. Competitive Scenario
      • 7.9.2.3. Regulatory Framework
      • 7.9.2.4. South Africa Market Estimates And Forecasts, 2018 To 2030 (USD Million)
    • 7.9.3. Saudi Arabia
      • 7.9.3.1. Key Country Dynamics
      • 7.9.3.2. Competitive Scenario
      • 7.9.3.3. Regulatory Framework
      • 7.9.3.4. Saudi Arabia Market Estimates And Forecasts, 2018 To 2030 (USD Million)
    • 7.9.4. UAE
      • 7.9.4.1. Key Country Dynamics
      • 7.9.4.2. Competitive Scenario
      • 7.9.4.3. Regulatory Framework
      • 7.9.4.4. UAE Market Estimates And Forecasts, 2018 To 2030 (USD Million)
    • 7.9.5. Kuwait
      • 7.9.5.1. Key Country Dynamics
      • 7.9.5.2. Competitive Scenario
      • 7.9.5.3. Regulatory Framework
      • 7.9.5.4. Kuwait Market Estimates And Forecasts, 2018 To 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company /Competition Categorization
  • 8.3. Vendor Landscape
    • 8.3.1. List Of Key Distributors And Channel Partners
    • 8.3.2. Key Customers
    • 8.3.3. Key Company Market Share Analysis, 2023
    • 8.3.4. CELONIC Group
      • 8.3.4.1. Overview
      • 8.3.4.2. Financial Performance
      • 8.3.4.3. Product Benchmarking
      • 8.3.4.4. Strategic Initiatives
    • 8.3.5. Bio Elpida
      • 8.3.5.1. Overview
      • 8.3.5.2. Financial Performance
      • 8.3.5.3. Product Benchmarking
      • 8.3.5.4. Strategic Initiatives
    • 8.3.6. Rentschler Biopharma SE
      • 8.3.6.1. Overview
      • 8.3.6.2. Financial Performance
      • 8.3.6.3. Product Benchmarking
      • 8.3.6.4. Strategic Initiatives
    • 8.3.7. AGC Biologics
      • 8.3.7.1. Overview
      • 8.3.7.2. Financial Performance
      • 8.3.7.3. Product Benchmarking
      • 8.3.7.4. Strategic Initiatives
    • 8.3.8. Catalent, Inc.
      • 8.3.8.1. Overview
      • 8.3.8.2. Financial Performance
      • 8.3.8.3. Product Benchmarking
      • 8.3.8.4. Strategic Initiatives
    • 8.3.9. Lonza
      • 8.3.9.1. Overview
      • 8.3.9.2. Financial Performance
      • 8.3.9.3. Product Benchmarking
      • 8.3.9.4. Strategic Initiatives
    • 8.3.10. Wuxi Advanced Therapies
      • 8.3.10.1. Overview
      • 8.3.10.2. Financial Performance
      • 8.3.10.3. Product Benchmarking
      • 8.3.10.4. Strategic Initiatives
    • 8.3.11. Minaris Regenerative Medicine
      • 8.3.11.1. Overview
      • 8.3.11.2. Financial Performance
      • 8.3.11.3. Product Benchmarking
      • 8.3.11.4. Strategic Initiatives
    • 8.3.12. Patheon, Inc.
      • 8.3.12.1. Overview
      • 8.3.12.2. Financial Performance
      • 8.3.12.3. Product Benchmarking
      • 8.3.12.4. Strategic Initiatives
    • 8.3.13. CGT Catapult
      • 8.3.13.1. Overview
      • 8.3.13.2. Financial Performance
      • 8.3.13.3. Product Benchmarking
      • 8.3.13.4. Strategic Initiatives